中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
10期
1314-1315
,共2页
铜绿假单胞菌%呼吸道感染%耐药性%抗菌药物
銅綠假單胞菌%呼吸道感染%耐藥性%抗菌藥物
동록가단포균%호흡도감염%내약성%항균약물
Pseudomonas aeruginosa%Lower respiratory tract infection%Drug resistance%Antibiotics
目的 了解我院铜绿假单胞菌的感染分布与耐药情况,为临床治疗提供依据.方法 对住院患者送检样本中培养分离出的403株铜绿假单胞菌的感染分布与耐药情况进行分析.采用稀释法进行药物敏感试验,结果按美国临床实验室标准化研究所标准判定.结果 铜绿假单胞菌主要来自痰标本(339株,84.1％),耐药率最高为头孢曲松(271株,67.2％),对亚胺培南的耐药率最低(61株15.1％),其次为哌拉西林/他唑巴坦(90株,22.3％),对其他11种抗菌药物的耐药率均较高.结论 铜绿假单胞菌主要引起呼吸道感染,对现有多种抗菌药物耐药严重,提示临床医生必须对该菌所致感染予以高度重视,关注易感人群,加强对该菌的监测,合理使用抗菌药物,以提高疗效和减缓耐药菌株的产生.
目的 瞭解我院銅綠假單胞菌的感染分佈與耐藥情況,為臨床治療提供依據.方法 對住院患者送檢樣本中培養分離齣的403株銅綠假單胞菌的感染分佈與耐藥情況進行分析.採用稀釋法進行藥物敏感試驗,結果按美國臨床實驗室標準化研究所標準判定.結果 銅綠假單胞菌主要來自痰標本(339株,84.1％),耐藥率最高為頭孢麯鬆(271株,67.2％),對亞胺培南的耐藥率最低(61株15.1％),其次為哌拉西林/他唑巴坦(90株,22.3％),對其他11種抗菌藥物的耐藥率均較高.結論 銅綠假單胞菌主要引起呼吸道感染,對現有多種抗菌藥物耐藥嚴重,提示臨床醫生必鬚對該菌所緻感染予以高度重視,關註易感人群,加彊對該菌的鑑測,閤理使用抗菌藥物,以提高療效和減緩耐藥菌株的產生.
목적 료해아원동록가단포균적감염분포여내약정황,위림상치료제공의거.방법 대주원환자송검양본중배양분리출적403주동록가단포균적감염분포여내약정황진행분석.채용희석법진행약물민감시험,결과안미국림상실험실표준화연구소표준판정.결과 동록가단포균주요래자담표본(339주,84.1％),내약솔최고위두포곡송(271주,67.2％),대아알배남적내약솔최저(61주15.1％),기차위고랍서림/타서파탄(90주,22.3％),대기타11충항균약물적내약솔균교고.결론 동록가단포균주요인기호흡도감염,대현유다충항균약물내약엄중,제시림상의생필수대해균소치감염여이고도중시,관주역감인군,가강대해균적감측,합리사용항균약물,이제고료효화감완내약균주적산생.
Objective To investigate the clinical distribution and drug resistance of pseudomonas aeruginosa and to offer basis for the clinical therapeutics.Methods The infection distribution and drug resistance of 403 samples of pseudomonas aeruginosa that were isolated from various kinds of specimens from inpatients were analyzed.The drug sensitivity test was done by means of dilution,and the resuhs were assessed with Clinical and Laboratory Standards Institute. Results The highest positive rate of pseudomonas aeruginosa was in sputum (84.1％).The resistance rates to ceftriaxone was high(271 strain,67.2％),the resistance rates to imipenem was the lowest(61 strain,15.1％)and piperacillin/tazobactam was 22.3％(90/403).Pseudomonas aeruginosa were high resistant to other 11 tested antibiotics. Conclusions Pseudomonas aeruginosa is a common pathogen of respiratory tract infection,which has a high resistance rate to the current clinical antibacterial agents. Consequently,clinical doctors should consider the infection results from pseudomonas aeruginosa to increase the positive effect and reduce drug resistance rate.
